share_log

New Data Published In Journal of the National Cancer Institute Demonstrate Veracyte's Decipher Prostate Genomic Classifier May Improve Identification Of Aggressive Prostate Cancer In African American Men

Benzinga Real-time News ·  Sep 22, 2022 08:58

Veracyte, Inc. (NASDAQ:VCYT) announced that data published today in theJournal of the National Cancer Institutedemonstrate that the company's Decipher Prostate Genomic Classifier may help identify African American men with early, localized prostate cancer who are most likely to harbor more aggressive disease. The data, from the prospective, multi-site VANDAAM Phase 2 clinical study, suggest that the genomic test may offer a robust improvement over clinical factors alone in risk-stratifying prostate cancer among African American men, which may help reduce disparities in prostate cancer outcomes.

"While African American men have both higher incidence and mortality associated...

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment